Alveltamig clinical trials
Also written ZG006.
How each study uses Alveltamig is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Alveltamig studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- ZG006
- 11
Studies by the year they started
11 studies that test it; most in 2025 (5)
| Year | Studies |
|---|---|
| 2023 | 1 |
| 2024 | 2 |
| 2025 | 5 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 11 · Other 0
Suzhou Zelgen Biopharmaceuticals Co.,Ltd (10) · Hansoh BioMedical R&D Company (1)
Often tested with
Tested in the same studies.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 3
Studies that test Alveltamig.
- Dec 2026A Phase 1 Dose Escalation Study of ZG006 in Patients With Small Cell Lung CancerPhase 1 · Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- Apr 2027Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Advanced Small Cell Lung CancerPhase 1/2 · Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- Sep 2027ZG006 and ZG005 in Participants With Small Cell Lung Cancer or Neuroendocrine CarcinomaPhase 1/2 · Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Studies
Open first, then newest update. How each study uses Alveltamig is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 11
- A Phase I Study of HS-20093 in Combination With ZG006 With or Without Adebrelimab in Patients With ES-SCLCNot yet recruitingPhase 1Hansoh BioMedical R&D CompanyNCT07892625Written as ZG006
- Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Advanced Small Cell Lung CancerRecruitingPhase 1/2Suzhou Zelgen Biopharmaceuticals Co.,LtdNCT06283719Written as ZG006
- A Study of ZG006 for Injection Versus Investigator-Selected Chemotherapy in Participants With Advanced Neuroendocrine CarcinomaNot yet recruitingPhase 3Suzhou Zelgen Biopharmaceuticals Co.,LtdNCT07595913Written as ZG006
- Study of ZG006 in Combination With PD-1/PD-L1 Immune Checkpoint Inhibitors as First-Line Standard Therapy in Participants With Extensive Stage Small-Cell Lung CancerRecruitingPhase 1Suzhou Zelgen Biopharmaceuticals Co.,LtdNCT07231445Written as ZG006
- Study of ZGGS34 in Participants With Advanced Solid TumorsRecruitingPhase 1/2Suzhou Zelgen Biopharmaceuticals Co.,LtdNCT07258121Written as ZG006
- Study of ZG006 in Participants With Small Cell Lung Cancer or Neuroendocrine CarcinomaRecruitingPhase 1/2Suzhou Zelgen Biopharmaceuticals Co.,LtdNCT05978284Written as ZG006
- ZG006 and ZG005 in Participants With Small Cell Lung Cancer or Neuroendocrine CarcinomaRecruitingPhase 1/2Suzhou Zelgen Biopharmaceuticals Co.,LtdNCT07038096Written as ZG006
- Study Comparing ZG006 With Investigator-Selected Chemotherapy in Participants With Relapsed Small Cell Lung CancerRecruitingPhase 3Suzhou Zelgen Biopharmaceuticals Co.,LtdNCT07189455Written as ZG006
- A Phase 1 Dose Escalation Study of ZG006 in Patients With Small Cell Lung CancerRecruitingPhase 1Suzhou Zelgen Biopharmaceuticals Co.,LtdNCT06592638Written as ZG006
- Study of ZG006 in Participants With Neuroendocrine Prostate CancerNot yet recruitingPhase 2Suzhou Zelgen Biopharmaceuticals Co.,LtdNCT07024277Written as ZG006
- Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Neuroendocrine Carcinoma.RecruitingPhase 1/2Suzhou Zelgen Biopharmaceuticals Co.,LtdNCT06440057Written as ZG006
Given beside what is tested · 1 — Alveltamig is usual care or a partner of the new treatment
What changed recently
From the registry's own updates since Oct 18, 2026.